Children with Low Vitamin K2 Status at Greater Risk for Fracture: Study

72bcbf88-0dae-4f01-ab94-e2a98ae53cfcarticleimage.jpg

14 Jun 2017 --- A new study abstract presented at the International Conference on Children’s Bone Health in Würzburg, Germany, has highlighted the increased risk of fracture in children with low vitamin K2 status. While vitamin D has an established role in the prevention of fractures, this is the first study to evaluate both D and K2 status in healthy children with low-energy fractures (i.e., the result of falling from standing height or less) and in the control group without fractures.

“Bone fractures are very common in children and their number is growing every year. Vitamin D has a proven role in the prevention of fractures… [but the] past decade has seen increased interest in the role of vitamin K, especially K2 menaquinone-7, in bone health and prevention of bone fractures,” the authors write. “There is a scarcity of research examining the effects of vitamin K deficiency on bone health in children and adolescent populations. The aim of the current study was to evaluate the vitamin D and K status in healthy children with low-energy fractures and in the control group without fractures.”

“This is a significant study as it supports what NattoPharma’s clinical research has already revealed: that children have the most pronounced K deficiency, making them most in need for K2 supplementation,” says Dr. Hogne Vik, Chief Medical Officer with NattoPharma. 

“NattoPharma's clinical trials with adult and child populations have shown that children have the greatest need for vitamin K2, as their bones are growing and developing so intensely, and confirmed that just 45mcg daily of MenaQ7 Vitamin K2 had a profound impact on children's bone health,” Kate Quackenbush, NattoPharma’s Director of Communications, tells NutritionInsight.

According to Vik, MenaQ7 Vitamin K2 increases the activation of osteocalcin, the K-dependent protein responsible for binding calcium to the bone mineral matrix, therefore improving bone health.

Click to EnlargeThe study group of 20 children aged 5 to 15 years old, with clinically confirmed low-energy fractures was compared with the control group of 19 healthy children, aged 7 to 17 years old, without fractures. Total vitamin D [25(OH)D3 plus 25(OH)D2], calcium, BALP (bone alkaline phosphatase), NTx (N-terminal telopeptide) and undercarboxylated (ucOC) and carboxylated osteocalcin (cOC) serum concentrations were evaluated in every patient. The ratio of serum undercarboxylated osteocalcin to serum carboxylated osteocalcin ucOC:cOC - UCR -  was used as an indicator of vitamin K status. Logistic regression models were created to establish UCR influence for the odds ratio of low-energy fractures in both groups.

The results revealed there were no statistically significant differences in the serum calcium, NTx, BALP or vitamin D levels between the groups; however, the statistically significant difference in the UCR was observed. The median UCR in the fracture group was 0.4709 compared with the control group value of 0.2445 (p<0.000004). In the logistic regression analysis, the odds ratio of fracture for UCR were calculated. The increase of the UCR by 0.1 increases the risk of fracture by 19.24 times (p=0.003).

“Children with bone fractures have two times lower vitamin K status expressed by UCR than healthy controls,” the authors write. “Increase of the UCR by 0.1 increases the risk of fracture by 9.62 times.”

“The better vitamin K status expressed as the ratio of ucOC: cOC - UCR - have positively and statistically significantly correlated with a lower rate of low-energy fracture incidence,” the authors conclude.

Speaking to NutritionInsight about the application opportunities for K2, Quackenbush says the company’s “ultimate goal is to see MenaQ7 Vitamin K2 as MK-7 as a core nutrient in all multivitamins, but in particular for kids and prenatal multis that provide a sound foundation for health as early as possible.”

“From a claims perspective, in Europe, due to EFSA regulations, health claims must be applied and awarded. We are hopeful that this will occur in the coming years, however, given EFSA's recent performance, this is yet to be seen,” she adds.

“In other parts of the world, the regulatory guidelines are different. Regardless, one must have scientific substantiation in the body of evidence that validates the claim. NattoPharma has extensive research including in vitro, in vivo, and 16 published human studies (with more underway), that clearly demonstrate the mechanism of vitamin K2 and the subsequent real health benefits such as preserving bone health and mass, and preserving arterial flexibility,” Quackenbush states. “The data is immutable, and based upon this evidence we are confident making strong statements about the efficacy of MenaQ7 Vitamin K2.”

Currently, manganese, protein, calcium, phosphorus and vitamin D are the predominant ingredients associated with bone health claims. Innova Market Insights has recorded a 36% increase in global product launch activity with a bone and/or joint health positioning in 2016 from 2015. While new product development for bone and joint health benefits is mostly contained to the dairy category, there is growing evidence of ingredient applications and claims made for products beyond the dairy aisle.  

To contact our editorial team please email us at editorial@cnsmedia.com

NattoPharma ASA

Collapse

As the leader in Vitamin K2 research & development, NattoPharma has not only created the Vitamin K2 category, but continues to drive it forward. Offering the best and first clinically validated and patented Vitamin K2 as MK-7 on the market, MenaQ7®, NattoPharma has sponsored the groundbreaking research that has confirmed K2’s essential role in bone and cardiovascular health, for old and young alike.

NattoPharma’s mission is to advance global health by creating and introducing to the market scientifically validated products and technologies that will deliver measurable health benefits and optimal health outcomes.

This mission is accomplished by:

• Addressing significant health concerns with branded, scientifically validated, proprietary products and technologies, leading with our flagship brand MenaQ7®;

• Leveraging all manner of technology to more effectively and efficiently deliver these products to our target markets;

• Solidifying ourselves as the experts in the science underlying our products and associated enabling technologies that allow us to effectively deliver them to the marketplace; and

• Developing and maintaining a deep customer and segment understanding of the benefits we deliver.

With 19+ published studies and even more underway, NattoPharma has an unparalleled patent portfolio related to relevant health benefits and market segments, creating extra values for its customers.  

MenaQ7® meets the growing demand for highly pure, stable K2 for supplemental and food use in any different format.

The most comprehensive Vitamin K2 ingredient portfolio meeting market needs:

MenaQ7® Natural MK-7: 96% pure all-trans MK-7 free of soy and other allergens.

MenaQ7® PharmaPure MK-7: The only all-trans nature-identical synthetic, winner of 2015   NutrAward for Best Functional Ingredient

MenaQ7® Natto MK-7: 96% active all-trans soy fermented MK-7

MenaQ7® Full Spectrum K2: The first and only K2 to deliver menaquinone isomers MK-6, 7, 8, and 9, free from soy and other allergens.

All material is available with CryoCap microencapsulation, ensuring stable menaquinone protection in any formulation.

The MenaQ7® brand is built upon 6 Pillars of Excellence, a platform delivering the most safe and efficacious Vitamin K2 on the market, creating opportunities for manufacturers and value for end users:

• Trusted Expertise

• Science Leader

• Superior Products

• Continuous Innovation

• Educational Marketing

• Cooperative Support

Visit website for more information: www.menaq7.com 

Related Articles

Health & Nutrition News

Obesity could overtake smoking as biggest preventable cause of cancer in women, says UK charity

24 Sep 2018 --- A new report by Cancer Research UK has put forward that obesity will overtake smoking as the biggest preventable cause of cancer among UK women in 25 years’ time. According to the report, by 2035, 10 percent of cancers in women (around 25,000 cases) could be caused by smoking and 9 percent (around 23,000 cases) by excess weight. If trends continue as projected, excess weight could cause even more cases of cancer than smoking in women by 2043.

Health & Nutrition News

Researchers aim to curb unhealthy weight gain in pregnant women using technological tools

24 Sep 2018 --- With proper nutritional guidance and technological tools, it is safe and feasible to restrict weight gain in obese pregnant women, a Northwestern Medicine study has found. The “novel” study, coined MOMFIT (Maternal Offspring Metabolics: Family Intervention Trial), was the first of its kind to include a commercially available smartphone app in the weight-loss approach, according to the research team.

Health & Nutrition News

Parents uncertain about young children’s dietary transitions, IFIC survey shows

24 Sep 2018 --- A majority of parents of children under 24 months old are confident that they are feeding them an age-appropriate and nutritious diet, a survey by the International Food Information Council (IFIC) Foundation has found. However, in addition to these positive findings, the survey also uncovered parents’ underlying concerns around issues like what foods to introduce into their kids’ diets and when. The survey, funded by the US National Yogurt Association, points to the need for clear, unambiguous information on what constitutes good children’s nutrition.

Health & Nutrition News

Grabbing the opportunity: Snacking NPD undergoes health transformation

24 Sep 2018 --- Consumers are increasingly seeking food options that are suitable for on the go consumption, as well as being nutritious. Traditional fast-food snacks may fall short as healthful demands prevail, spurring ample NPD and innovation in an array of market areas. Nutrition on the go is becoming more achievable as healthier foods package themselves in on the go friendly formats, as well as established snacking options undergoing healthy transformations. 

Health & Nutrition News

Fish-rich diet during pregnancy may boost baby's brain development

21 Sep 2018 --- Regularly eating fatty fish during pregnancy could boost the development of an unborn child's eyesight and brain function, according to a small-scale study led by Kirsi Laitinen of the University of Turku and Turku University Hospital in Finland. Published in the journal Pediatric Research, the results support previous findings that show how important a mother's diet and lifestyle choices during pregnancy are for the development of her baby.

More Articles
URL : http://www.nutritioninsight.com:80/news/children-with-low-vitamin-k2-status-at-greater-risk-for-fracture-study.html